Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Evaluating the Trump Administration's New MFN Medicaid GENEROUS Model" report has been added to ResearchAndMarkets.com's offering.
Since the US president Donald Trump issued the Most Favored Nation (MFN) executive order, several pharmaceutical companies have agreed to comply with MFN pricing and more are expected to fall in line in the future.
The Trump administration also recently revealed a new program for Medicaid, dubbed the GENErating cost Reductions for U.S. Medicaid (GENEROUS) model, where State Medicaid programs will be able to purchase drugs at MFN prices. The GENEROUS model revealed details on how international reference pricing (IRP) will be introduced into the US. The analyst therefore examines the impact of this model for pharma companies.
Key Topics Covered:
- Key findings
- Smaller basket of comparator countries in the GENEROUS model
For more information about this report visit https://www.researchandmarkets.com/r/1fjmdk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
